Sequencing Impact and Prognostic Factors in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel: A Systematic Review and Meta-Analysis

Takafumi Yanagisawa,Tatsushi Kawada,Pawel Rajwa,Hadi Mostafaei,Reza Sari Motlagh,Fahad Quhal,Ekaterina Laukhtina,Frederik König,Maximilian Pallauf,Benjamin Pradere,Pierre I. Karakiewicz,Peter Nyirady,Takahiro Kimura,Shin Egawa,Shahrokh F. Shariat

Urologic Oncology Seminars and Original Investigations（2023）

引用 2|浏览32

暂无评分

摘要

•Sequential therapy with cabazitaxel improves OS in post-docetaxel mCRPC patients.•Poor PS, visceral metastasis, and symptomatic disease were prognostic factors for OS.•Pretreatment high PSA, ALP, LDH or CRP were blood-based prognostic factors for OS.•Pretreatment low hemoglobin or albumin were also blood-based prognostic factors for OS.•These findings might help guide the clinical decision-making for the use of cabazitaxel.

查看译文

关键词

Metastatic castration-resistant prostate cancer,Cabazitaxel,Prognostic factor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要